I was a little negative re the vaccine business and will need convincing for its full retention. I believe that the average annual spend is $2.5m. If we get the $1.5m research grant based on the vaccine work then that might convince the market to retain the vaccine division as the potential is only costing $1m net per annum unless the adapt work qualifies partially for the grant.Clarification would be welcome. I would prefer to partner the vaccine business as the time frame is lengthy and will be a distraction for the adapt progress which I expect in the next quarter or two.
any reason for share price wilting?, page-18
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |